Chai Discovery has partnered with Eli Lilly to use its Chai-2 algorithm for antibody design, followi...
The AMW Read
Updates the player map for the Bio-platform cluster with a significant Series B and a major strategic partnership between an AI lab and a pharmaceutical incumbent.
NoveltySignificance
Healthcare & Bio · Player Map
Chai Discovery has partnered with Eli Lilly to use its Chai-2 algorithm for antibody design, following a 130 million dollar Series B valuing the firm at 1.3 billion dollars. This collaboration shifts R&D from trial-and-error to generative design with double-digit experimental hit rates. By targeting clinical trials by 2027, the deal demonstrates AI's power to compress decade-long development cycles. This is a systemic leap toward data-native pharmaceutical infrastructure. 🧬🔬
